MUMBAI, India, March 13 -- Intellectual Property India has published a patent application (202621000768 A) filed by Dr. Rajesh Hadia; Dr. Rajesh Maheshwari; Dr. Dipika Bhil; and Dr. Hemraj Singh Rajput, Vadodara, Gujarat, on Jan. 5, for 'a system and method for monitoring, assessing, preventing and clinically managing hydroxyurea-induced adverse drug reactions in pediatric sickle cell disease patients.'
Inventor(s) include Dr. Rajesh Hadia; Dr. Rajesh Maheshwari; Dr. Dipika Bhil; and Dr. Hemraj Singh Rajput.
The application for the patent was published on March 13, under issue no. 11/2026.
According to the abstract released by the Intellectual Property India: "The present invention discloses a comprehensive system and method for monitoring, assessing, preventing, and clinically managing hydroxyurea-induced adverse drug reactions in pediatric patients with sickle cell disease. The invention integrates structured patient profiling, validated ADR assessment scales, pharmacist-led interventions, preventive strategies, standardized documentation, and cost analysis to improve patient safety, therapeutic outcomes, and pharmacovigilance efficiency."
Disclaimer: Curated by HT Syndication.
